ATC codes:
L01AA09
Indication
Chronic lymphocytic leukaemia or small lymphocytic lymphoma
ICD11 code:
2B52.0
INN
Bendamustine
Medicine type
Chemical agent
List type
Complementary
Formulations
Parenteral > General injections > unspecified:
45 mg per 0.5 mL ;
180 mg per 2 mL
EML status history
First added in 2015
(TRS
994)
Sex
All
Age
Adolescents and adults
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Main patents have expired but secondary patents might remain active in some jurisdictions. For more
information on specific patents and license status for developing countries visit www.MedsPal.org
Read more
about patents.
Summary of evidence and Expert Committee recommendations
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, bendamustine was added to the complementary list of the EML for use in treatment protocols for chronic lymphocytic leukaemia.
The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for chronic lymphocytic leukaemia is attached.